Jason N. Thompson

Array ( [id] => 17556092 [patent_doc_number] => 11312768 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-04-26 [patent_title] => Signature of TL1A (TNFSF15) signaling pathway [patent_app_type] => utility [patent_app_number] => 16/388101 [patent_app_country] => US [patent_app_date] => 2019-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 58 [patent_no_of_words] => 9847 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16388101 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14685109 [patent_doc_number] => 20190241669 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-08 [patent_title] => CHIMERIC ANTIGEN RECEPTORS TARGETING B-CELL MATURATION ANTIGEN [patent_app_type] => utility [patent_app_number] => 16/384719 [patent_app_country] => US [patent_app_date] => 2019-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42173 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16384719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14712869 [patent_doc_number] => 20190247498 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/384521 [patent_app_country] => US [patent_app_date] => 2019-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20279 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16384521 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15496337 [patent_doc_number] => 20200048357 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => BCMA AND CD3 BISPECIFIC T CELL ENGAGING ANTIBODY CONSTRUCTS [patent_app_type] => utility [patent_app_number] => 16/373083 [patent_app_country] => US [patent_app_date] => 2019-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45504 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16373083 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19121205 [patent_doc_number] => 11965176 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-23 [patent_title] => Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy [patent_app_type] => utility [patent_app_number] => 16/980237 [patent_app_country] => US [patent_app_date] => 2019-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 10 [patent_no_of_words] => 17926 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16980237 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14777989 [patent_doc_number] => 20190263892 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => FIBRONECTIN BASED SCAFFOLD PROTEINS HAVING IMPROVED STABILITY [patent_app_type] => utility [patent_app_number] => 16/298493 [patent_app_country] => US [patent_app_date] => 2019-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26062 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16298493 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16621571 [patent_doc_number] => 20210040224 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => CD47 BLOCKADE THERAPY WITH CD38 ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/979707 [patent_app_country] => US [patent_app_date] => 2019-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6075 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16979707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16590591 [patent_doc_number] => 10899841 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-01-26 [patent_title] => Anti-BAFFR antibody formulations and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/294374 [patent_app_country] => US [patent_app_date] => 2019-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10909 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16294374 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16042985 [patent_doc_number] => 10683351 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-16 [patent_title] => Antibody constructs for DLL3 and CD3 [patent_app_type] => utility [patent_app_number] => 16/291826 [patent_app_country] => US [patent_app_date] => 2019-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 14 [patent_no_of_words] => 50348 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16291826 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16718638 [patent_doc_number] => 20210085785 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => TREATING CANCER BY BLOCKING THE INTERACTION OF VISTA AND ITS BINDING PARTNER [patent_app_type] => utility [patent_app_number] => 16/971559 [patent_app_country] => US [patent_app_date] => 2019-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19391 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -79 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16971559 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16482436 [patent_doc_number] => 20200376036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => METHODS OF REGULATORY T CELL EXPANSION AND ACTIVATION [patent_app_type] => utility [patent_app_number] => 16/970792 [patent_app_country] => US [patent_app_date] => 2019-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9974 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -135 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16970792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14833455 [patent_doc_number] => 20190275128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-12 [patent_title] => USE OF TOLL-LIKE RECEPTOR AGONIST FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 16/279457 [patent_app_country] => US [patent_app_date] => 2019-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23198 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16279457 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16673154 [patent_doc_number] => 20210061917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING VITILIGO [patent_app_type] => utility [patent_app_number] => 16/970034 [patent_app_country] => US [patent_app_date] => 2019-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8021 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16970034 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16557236 [patent_doc_number] => 20210002384 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => PROCESS FOR PRODUCING HU14.18K322A MONOCLONAL ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/969733 [patent_app_country] => US [patent_app_date] => 2019-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8069 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16969733 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17974369 [patent_doc_number] => 11491206 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-11-08 [patent_title] => Compositions and methods for the treatment of trail-resistant cancer [patent_app_type] => utility [patent_app_number] => 16/274978 [patent_app_country] => US [patent_app_date] => 2019-02-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 61 [patent_no_of_words] => 16224 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16274978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18427669 [patent_doc_number] => 11672870 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-13 [patent_title] => Transduction [patent_app_type] => utility [patent_app_number] => 16/266535 [patent_app_country] => US [patent_app_date] => 2019-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 60 [patent_figures_cnt] => 43 [patent_no_of_words] => 27637 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16266535 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16482430 [patent_doc_number] => 20200376030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-03 [patent_title] => CHIMERIC ANTIGEN RECEPTOR (CAR) BINDING TO BCMA, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/650327 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16882 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16650327 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14306333 [patent_doc_number] => 20190142870 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => ENHANCED RECONSTITUTION AND AUTORECONSTITUTION OF THE HEMATOPOIETIC COMPARTMENT [patent_app_type] => utility [patent_app_number] => 16/261207 [patent_app_country] => US [patent_app_date] => 2019-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45093 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16261207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20129177 [patent_doc_number] => 12371479 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-29 [patent_title] => Anti-elastin antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 17/423999 [patent_app_country] => US [patent_app_date] => 2019-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 41 [patent_no_of_words] => 8321 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17423999 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14534545 [patent_doc_number] => 20190202894 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => TARGETED THERAPEUTICS BASED ON ENGINEERED PROTEINS FOR TYROSINE KINASES RECEPTORS, INCLUDING IGF-IR [patent_app_type] => utility [patent_app_number] => 16/244851 [patent_app_country] => US [patent_app_date] => 2019-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43244 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16244851 [rel_patent_id] =>[rel_patent_doc_number] =>)